MX364633B - Uso de cannabinoides en el tratamiento de enfermedades degenerativas del músculo esquelético. - Google Patents
Uso de cannabinoides en el tratamiento de enfermedades degenerativas del músculo esquelético.Info
- Publication number
- MX364633B MX364633B MX2017004761A MX2017004761A MX364633B MX 364633 B MX364633 B MX 364633B MX 2017004761 A MX2017004761 A MX 2017004761A MX 2017004761 A MX2017004761 A MX 2017004761A MX 364633 B MX364633 B MX 364633B
- Authority
- MX
- Mexico
- Prior art keywords
- cannabinoids
- skeletal muscle
- treatment
- muscle diseases
- degenerative skeletal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La presente invención se refiere al uso de cannabinoides en el tratamiento de una enfermedad degenerativa del músculo esquelético. En particular, la enfermedad degenerativa del músculo esquelético es distrofia muscular de Duchenne (DMD). Preferiblemente, los cannabinoides son uno o más de: cannabidiol (CBD); cannabidivarina (CBDV) y tetrahidrocannabivarina (THCV).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1418172.1A GB2531283A (en) | 2014-10-14 | 2014-10-14 | Use of cannabidiols in the treatment of degenerative skeletal muscle diseases |
PCT/GB2015/053044 WO2016059411A1 (en) | 2014-10-14 | 2015-10-14 | Use of cannabinoids in the treatment of degenerative skeletal muscle diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2017004761A MX2017004761A (es) | 2017-07-27 |
MX364633B true MX364633B (es) | 2019-05-03 |
Family
ID=52001394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017004761A MX364633B (es) | 2014-10-14 | 2015-10-14 | Uso de cannabinoides en el tratamiento de enfermedades degenerativas del músculo esquelético. |
Country Status (11)
Country | Link |
---|---|
US (1) | US10226433B2 (es) |
EP (1) | EP3206681B1 (es) |
JP (1) | JP6655076B2 (es) |
AU (1) | AU2015332220B2 (es) |
BR (1) | BR112017007774A2 (es) |
CA (1) | CA2963211C (es) |
ES (1) | ES2732062T3 (es) |
GB (1) | GB2531283A (es) |
IL (1) | IL251530B (es) |
MX (1) | MX364633B (es) |
WO (1) | WO2016059411A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3509638T (pt) | 2017-06-20 | 2022-03-02 | Univ Guelph | Composições de ésteres de ácido canabidiólico e suas utilizações |
WO2019025474A1 (en) * | 2017-08-02 | 2019-02-07 | Centro Cardiologico Monzino S.p.A. | MODULATION OF ENDOCANNABINOID SYSTEM AND USES IN THE CONTEXT OF INDUCED PLURIPOTENT STEM CELL-BASED APPLICATIONS AND THERAPY FOR CARDIOMYOPATHIES |
CN113116869B (zh) * | 2019-12-31 | 2022-08-23 | 汉义生物科技(北京)有限公司 | 一种预防和/或治疗抑郁的组合物 |
WO2021137224A1 (en) * | 2020-01-01 | 2021-07-08 | Epm Group, Inc. | Cannabidiolic acid esters for treating muscular dystrophy |
WO2022122904A1 (en) | 2020-12-09 | 2022-06-16 | Chanelle Mccoy Cbd Limited | A delayed-release capsule of cannabidiol |
WO2024043242A1 (ja) * | 2022-08-23 | 2024-02-29 | 国立大学法人九州大学 | Trpc3/6/7チャネル活性化による強心作用を介した心不全治療 |
-
2014
- 2014-10-14 GB GB1418172.1A patent/GB2531283A/en not_active Withdrawn
-
2015
- 2015-10-14 ES ES15784121T patent/ES2732062T3/es active Active
- 2015-10-14 EP EP15784121.4A patent/EP3206681B1/en active Active
- 2015-10-14 WO PCT/GB2015/053044 patent/WO2016059411A1/en active Application Filing
- 2015-10-14 JP JP2017520535A patent/JP6655076B2/ja active Active
- 2015-10-14 BR BR112017007774A patent/BR112017007774A2/pt not_active Application Discontinuation
- 2015-10-14 AU AU2015332220A patent/AU2015332220B2/en active Active
- 2015-10-14 CA CA2963211A patent/CA2963211C/en active Active
- 2015-10-14 MX MX2017004761A patent/MX364633B/es active IP Right Grant
- 2015-10-14 US US15/518,297 patent/US10226433B2/en active Active
-
2017
- 2017-04-03 IL IL25153017A patent/IL251530B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
MX2017004761A (es) | 2017-07-27 |
IL251530B (en) | 2019-10-31 |
IL251530A0 (en) | 2017-05-29 |
WO2016059411A1 (en) | 2016-04-21 |
AU2015332220B2 (en) | 2020-10-01 |
BR112017007774A2 (pt) | 2018-01-16 |
CA2963211A1 (en) | 2016-04-21 |
GB201418172D0 (en) | 2014-11-26 |
JP2018502823A (ja) | 2018-02-01 |
CA2963211C (en) | 2023-09-05 |
JP6655076B2 (ja) | 2020-02-26 |
AU2015332220A1 (en) | 2017-04-20 |
US10226433B2 (en) | 2019-03-12 |
EP3206681A1 (en) | 2017-08-23 |
ES2732062T3 (es) | 2019-11-20 |
GB2531283A (en) | 2016-04-20 |
US20170304217A1 (en) | 2017-10-26 |
EP3206681B1 (en) | 2019-04-10 |
NZ730985A (en) | 2024-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017004761A (es) | Uso de cannabinoides en el tratamiento de enfermedades degenerativas del musculo esqueletico. | |
MX2022008278A (es) | Uso de cannabinoides para el tratamiento de epilepsia. | |
EA201290975A8 (ru) | Применение фитоканнабиноида каннабидиварина (cbdv) для лечения эпилепсии | |
EA201791299A1 (ru) | Микроинкапсулированные композиции каннабиноидов | |
CO2019001043A2 (es) | Composición de cannabis | |
BR112016020618A8 (pt) | oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido | |
NZ726746A (en) | Stable cannabinoid formulations | |
CO7101245A2 (es) | Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido | |
PE20170931A1 (es) | Nuevas normalizaciones y dispositivos medicos para la preparacion de plasma rico en plaquetas (prp) o concentrado de medula osea (bmc) solos o combinados con acido hialuronico | |
PE20200338A1 (es) | Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil | |
BR112018007958A2 (pt) | composições e métodos que usam um polifenol para a saúde musculoesquelética | |
MX2017004772A (es) | Composiciones y métodos para la administración fisiológica utilizando cannabidiol. | |
PH12016501965A1 (en) | S1p modulator immediate release dosage regimen | |
EP4137147A3 (en) | Uses of abaloparatide in reducing fracture risk | |
MX2020004232A (es) | Composiciones de cannabinoides y sus metodos de uso. | |
MX2020012800A (es) | Cannabinoides y usos de los mismos. | |
BR112017026834A2 (pt) | composição compreendendo vitaminas b e vitaminas c e seu uso | |
MX2018001965A (es) | Formulaciones liquidas que contienen picosulfato y citrato de magnesio. | |
CO6731081A2 (es) | Método para producir y usar un copolímero de carboximetilcelulosa sódica y gosipol | |
BR112017007364A2 (pt) | composição farmacêutica para o uso no tratamento ou prevenção de deficiências de vitaminas e minerais em pacientes que foram submetidos à cirurgia de bypass gástrico | |
MX364528B (es) | Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas. | |
NZ756307A (en) | Formulations of cannabinoids for the treatment of acne | |
EP3270883A4 (en) | Scalable vitamin composition unit dosage for the treatment of fat-soluble vitamin deficiencies | |
BR112016028402A2 (pt) | toxina botulínica para uso no tratamento da paratonia | |
BR112017003881A2 (pt) | derivados do n-aril-2-amino-4-aril-pirimidinas poliéteres macrocíclicos como inibidores da ftl3 e jak |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |